Fundraising Fox
Endo
Malvern, US · Founded 2023 · Delaware corporation · 2 known investors
Find your way into Endo
Sign up to see every warm intro you have to Endo
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Endo team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Keenova is a specialty therapeutics company focused on rare, stigmatized, or unaddressed conditions across areas including immunology, urology, hepatology, ophthalmology, orthopedics, and critical care. Par Health develops generic pharmaceuticals, sterile injectables, and active pharmaceutical ingredients with U.S.-based manufacturing capabilities.
Founders & leadership
BC
Blaise ColemanPresident and CEO, Board Member2020–2024Blaise Coleman held executive leadership roles at Johnson & Johnson and AstraZeneca before serving as President and CEO of Endo, where he oversaw operational improvements and financial restructuring. He holds an MBA from Duke University's Fuqua School of Business and a BS from Widener University, with background in accounting and finance.
MB
Mark BradleyEVP, Chief Financial Officer2020–2025Mark Bradley is Chief Financial Officer and Executive Vice President at Endo, a specialty therapeutics company developing treatments for rare and stigmatized conditions. He brings experience in global financial operations, capital markets transactions, corporate development, and financial restructuring.
SH
Scott HirschNamed on SEC filing
PE
Paul EfronNamed on SEC filing
PH
Paul HerendeenNamed on SEC filing
MY
Marc YoskowitzNamed on SEC filing
PB
Patrick BarryNamed on SEC filing
SL
Sophia LangloisNamed on SEC filing
AP
Andy PasternakNamed on SEC filing
Investors · 2
Reported raises · per SEC filings
Form D private placements$170.6M disclosed across 1 round · 2024
▶$170.6MraisedMay 2024 · 404 investors · PharmaceuticalsRule 506(b)
▶$170.6MraisedMay 2024 · 404 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Scott HirschDirector
- Paul EfronDirector
- Paul HerendeenDirector
- Marc YoskowitzDirector
- Patrick BarryExecutive Officer
- Blaise ColemanExecutive Officer, Director
- Matthew MalettaExecutive Officer
- Sophia LangloisDirector
- Frank RacitiExecutive Officer
- Mark BradleyExecutive Officer, Director
- Andy PasternakDirector
- Offering amount
- $170.6M
- Amount sold
- $170.6M
- First sale
- Mar 2024
- Incorporated
- Corporation, Delaware, 2023
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 1
Companies working in the same space as Endo.
Frequently asked questions
- What does Endo do?
- Keenova is a specialty therapeutics company focused on rare, stigmatized, or unaddressed conditions across areas including immunology, urology, hepatology, ophthalmology, orthopedics, and critical care. Par Health develops generic pharmaceuticals, sterile injectables, and active pharmaceutical ingredients with U.S.-based manufacturing capabilities.
- Who are Endo's investors?
- Endo's investors include Accelmed Partners, Signet Healthcare Partners.
- How much funding has Endo raised?
- Endo has disclosed $170.6M raised across 1 round.
- Where is Endo headquartered?
- Endo is headquartered in Malvern, US.